-DOCSTART- -X- O
ABSTRACT -X- _ O
: -X- _ O
Adult-onset -X- _ B-Patient
Still’s -X- _ I-Patient
Disease -X- _ I-Patient
( -X- _ I-Patient
AOSD -X- _ I-Patient
) -X- _ I-Patient
since -X- _ O
its -X- _ O
description -X- _ O
in -X- _ O
1971 -X- _ O
has -X- _ O
proven -X- _ O
to -X- _ O
be -X- _ O
a -X- _ O
very -X- _ O
complex -X- _ O
and -X- _ O
challenging -X- _ O
disease -X- _ O
entity. -X- _ O
This -X- _ O
rare -X- _ O
auto-inflammatory -X- _ O
disease -X- _ O
is -X- _ O
classically -X- _ O
described -X- _ O
by -X- _ O
the -X- _ O
“Still’s -X- _ O
triad” -X- _ O
of -X- _ O
fever -X- _ O
, -X- _ O
rash -X- _ O
, -X- _ O
and -X- _ O
arthritis -X- _ O
, -X- _ O
although -X- _ O
the -X- _ O
atypical -X- _ O
cases -X- _ O
frequently -X- _ O
outnumber -X- _ O
the -X- _ O
typical -X- _ O
ones. -X- _ O
The -X- _ O
exact -X- _ O
pathogenesis -X- _ O
and -X- _ O
etiologic -X- _ O
factors -X- _ O
responsible -X- _ O
for -X- _ O
the -X- _ O
clinical -X- _ O
features -X- _ O
remain -X- _ O
largely -X- _ O
obscure -X- _ O
, -X- _ O
despite -X- _ O
recent -X- _ O
suggestive -X- _ O
cytokine -X- _ O
biology -X- _ O
findings. -X- _ O
Diagnosis -X- _ O
is -X- _ O
made -X- _ O
on -X- _ O
clinical -X- _ O
grounds -X- _ O
, -X- _ O
following -X- _ O
the -X- _ O
exclusion -X- _ O
of -X- _ O
mimickers -X- _ O
of -X- _ O
infectious -X- _ O
, -X- _ O
autoimmune -X- _ O
or -X- _ O
neoplastic -X- _ O
etiology -X- _ O
, -X- _ O
with -X- _ O
the -X- _ O
additional -X- _ O
consideration -X- _ O
of -X- _ O
non-specific -X- _ O
laboratory -X- _ O
abnormalities -X- _ O
such -X- _ O
as -X- _ O
peripheral -X- _ O
leukocytosis -X- _ O
and -X- _ O
elevation -X- _ O
of -X- _ O
serum -X- _ O
ferritin -X- _ O
and -X- _ O
other -X- _ O
acute -X- _ O
phase -X- _ O
reactants. -X- _ O
The -X- _ O
disease -X- _ O
manifestations -X- _ O
are -X- _ O
protean -X- _ O
and -X- _ O
can -X- _ O
include -X- _ O
diverse -X- _ O
complications -X- _ O
, -X- _ O
affecting -X- _ B-Outcome
multiple -X- _ I-Outcome
organ -X- _ I-Outcome
systems. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
severity -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
organ -X- _ I-Outcome
involvement -X- _ I-Outcome
can -X- _ I-Outcome
vary -X- _ I-Outcome
considerably -X- _ I-Outcome
, -X- _ I-Outcome
representing -X- _ I-Outcome
a -X- _ I-Outcome
wide -X- _ I-Outcome
spectrum -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
self-limited -X- _ I-Outcome
to -X- _ I-Outcome
severe. -X- _ I-Outcome
The -X- _ O
mainstay -X- _ O
of -X- _ O
therapy -X- _ O
has -X- _ O
evolved -X- _ O
from -X- _ O
the -X- _ O
traditional -X- _ O
use -X- _ O
of -X- _ O
corticosteroids -X- _ O
and -X- _ O
oral -X- _ O
immunosupressants -X- _ O
to -X- _ O
the -X- _ O
newer -X- _ O
targeted -X- _ O
treatments -X- _ O
with -X- _ O
biologic -X- _ O
agents. -X- _ O
The -X- _ O
scope -X- _ O
of -X- _ O
this -X- _ O
review -X- _ O
is -X- _ O
to -X- _ O
alert -X- _ O
the -X- _ O
clinician -X- _ O
to -X- _ O
the -X- _ O
existence -X- _ O
of -X- _ O
life-threatening -X- _ O
AOSD -X- _ O
complications -X- _ O
, -X- _ O
namely -X- _ O
the -X- _ O
macrophage -X- _ B-Outcome
activation -X- _ I-Outcome
syndrome -X- _ I-Outcome
, -X- _ I-Outcome
disseminated -X- _ I-Outcome
intravascular -X- _ I-Outcome
coagulopathy -X- _ I-Outcome
, -X- _ I-Outcome
thrombotic -X- _ I-Outcome
thrombocytopenic -X- _ I-Outcome
purpura -X- _ I-Outcome
, -X- _ I-Outcome
diffuse -X- _ I-Outcome
alveolar -X- _ I-Outcome
hemorrhage -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
pulmonary -X- _ I-Outcome
arterial -X- _ I-Outcome
hypertension. -X- _ I-Outcome
Such -X- _ O
knowledge -X- _ O
may -X- _ O
lead -X- _ O
in -X- _ O
earlier -X- _ O
recognition -X- _ O
, -X- _ O
prompt -X- _ O
treatment -X- _ O
, -X- _ O
and -X- _ O
, -X- _ O
ideally -X- _ O
, -X- _ O
improved -X- _ O
patient -X- _ O
outcomes -X- _ O
. -X- _ O

